

101554109  
20050709 21 OCT 2005

**THE FOLLOWING ARE THE ENGLISH TRANSLATION  
OF ANNEXES TO THE INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT (ARTICLE 34):**

## Amended Specification (Pages 60-63)

## Claims

1. (After Amendment) A therapeutic agent for  
Parkinson's disease, cerebral infarction, head injuries,  
5 cerebral hemorrhage, spinal injuries, which comprises a PPAR $\delta$   
agonist as an active ingredient.

2. (After Amendment) A therapeutic method for  
Parkinson's disease, cerebral infarction, head injuries,  
10 cerebral hemorrhage, spinal injuries, which comprises  
administering a pharmaceutical agent comprising a PPAR $\delta$   
agonist as an active ingredient.

3. A therapeutic agent for cerebral infarction,  
15 which comprises a PPAR $\delta$  agonist as an active ingredient.

4. A therapeutic agent for Parkinson's disease,  
which comprises a PPAR $\delta$  agonist as an active ingredient.

20 5. A therapeutic method for cerebral infarction,  
which comprises administering a pharmaceutical agent  
comprising a PPAR $\delta$  agonist as an active ingredient.

25 6. A therapeutic method for Parkinson's disease,  
which comprises administering a pharmaceutical agent  
comprising a PPAR $\delta$  agonist as an active ingredient.

7. The therapeutic agent according to claim 1, 3  
or 4, wherein the PPAR $\delta$  agonist is a PPAR $\delta$  agonist  
specifically re-selected using the activity of suppressing  
5 cellular death as the marker.

8. The therapeutic method according to claim 2, 5  
or 6, wherein the PPAR $\delta$  agonist is a PPAR $\delta$  agonist  
specifically re-selected using the activity of suppressing  
10 cellular death as the marker.

9. The therapeutic agent according to claim 1, 3  
or 4, wherein the PPAR $\delta$  agonist is L-165041 or GW501516.

15 10. The therapeutic method according to claim 2, 5  
or 6, wherein the PPAR $\delta$  agonist is L-165041 or GW501516.

20 11. (After Amendment) Use of a PPAR $\delta$  agonist for  
the manufacture of a therapeutic agent for Parkinson's  
disease, cerebral infarction, head injuries, cerebral  
hemorrhage, spinal injuries.

12. Use of a PPAR $\delta$  agonist for the manufacture of a  
therapeutic agent for cerebral infarction.

13. Use of a PPAR $\delta$  agonist for the manufacture of a therapeutic agent for Parkinson's disease.

14. The use according to any of claims 11 through 5 13, wherein the PPAR $\delta$  agonist is a PPAR $\delta$  agonist specifically re-selected using the activity of suppressing cellular death as the marker.

15. The use according to any of claims 11 through 10 13, wherein the PPAR $\delta$  agonist is a PPAR $\delta$  agonist specifically re-selected using the activity of suppressing cellular death as the marker.

16. An agent of suppressing the death of central 15 nerve cell, which comprises a PPAR $\delta$  agonist as an active ingredient.

17. The agent of suppressing the death of central nerve cell according to claim 16, wherein the PPAR $\delta$  agonist 20 is L-165041 or GWW501516.

18. (addition) An agent of suppressing the death of central nerve cell in cerebral hemorrhage, which comprises a PPAR $\delta$  agonist as an active ingredient.

19. (addition) An agent of suppressing the death of central nerve cell in acute stage of cerebral infarction, which comprises a PPAR $\delta$  agonist as an active ingredient.